Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension

NCT00257413•Zhejiang University

Summary

Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. In addition, clinical studies suggest that autogolous progenitor cells transplantation is feasible and safe in patients with ischemic disease. This study will investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous EPCs in patients with idiopathic pulmonary arterial hypertension.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of idiopathic pulmonary arterial hypertension
•in New York Heart Association (NYHA) functional class II to III
•a mean pulmonary artery pressure more than 30 mmHg on right heart catheterization
•the ability to walk ≥50 m during a standardized 6-minute walk test.

Exclusion Criteria

•Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, NYHA functional class IV, major bleeding requiring blood transfusion, diabetes, renal dysfunction, and evidence for malignant diseases were excluded

Locations (1)

Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Key Dates

Last Updated

November 22, 2005

Conditions

Idiopathic Pulmonary Arterial Hypertension

Interventions

Transplantation of autologous endothelial progenitor cells

PROCEDURE

Empagliflozin in Pulmonary Arterial Hypertension

NCT05493371

Idiopathic Pulmonary Arterial Hypertension

View study

COMPLETEDNA

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716

Pulmonary Arterial HypertensionIdiopathic Pulmonary Arterial Hypertension+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension

Inclusion Criteria

Exclusion Criteria

Empagliflozin in Pulmonary Arterial Hypertension

A Mobile Health Intervention in Pulmonary Arterial Hypertension

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension